Resmed Stock News

In recent trading, shares of ResMed Inc. (Symbol: RMD) have crossed above the average analyst 12-month target price of $261.50, changing hands for $262.37/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst [] The post RMD Crosses Above Average Analyst Target appeared first on UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News .

Squarepoint Ops LLC trimmed its position in shares of ResMed Inc. (NYSE:RMD) by 92.4% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,115 shares of the medical equipment providers stock after selling 25,711 shares during the period. Squarepoint Ops LLCs holdings []

Beacon Pointe Advisors LLC acquired a new position in shares of ResMed Inc. (NYSE:RMD) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 849 shares of the medical equipment providers stock, valued at approximately $209,000. Several other hedge funds and other []

A big update to the life expectancy calculations done in required minimum distribution (RMD) tables is coming next year, and it means less money will have to be withdrawn annually. It's a potential bo

NEW YORK , Nov. 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RIOT, AMC, RMD, ETSY, and NFLX. … Full story available on Benzinga.com

ResMed Inc. (NYSE:RMD) CFO Brett Sandercock sold 2,500 shares of ResMed stock in a transaction that occurred on Wednesday, November 10th. The shares were sold at an average price of $260.58, for a total value of $651,450.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through []

First Trust Advisors LP lessened its holdings in ResMed Inc. (NYSE:RMD) by 78.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 14,369 shares of the medical equipment providers stock after selling 51,208 shares during the period. First Trust Advisors LPs holdings in []

ResMed (RMD) reports better-than-expected earnings and revenues with robust demand for sleep and respiratory care devices driving Q1 top line.

ResMed Inc. (RMD) CEO Mick Farrell on Q1 2022 Results - Earnings Call Transcript

Strong customer demand and new product launches are likely to contribute to growth in the fiscal first quarter for ResMed (RMD).

SAN DIEGO, Oct. 07, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2022 on Thursday, O

Investors are optimistic about ResMed (RMD) owing to new product launches in the SDB market and strong sales of mask products.

ResMed Inc.: Best Price-Positioned Medical Supply Industry Stock, As Seen By Market-Makers

SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a virtual fireside chat at the Bank o